- Home
- SYBX vs HOTH Comparison
SYBX vs HOTH Comparison
Compare SYBX & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- HOTH
- Stock Information
- Founded
- SYBX N/A
- HOTH 2017
- Country
- SYBX United States
- HOTH United States
- Employees
- SYBX N/A
- HOTH N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- HOTH Health Care
- Exchange
- SYBX Nasdaq
- HOTH Nasdaq
- Market Cap
- SYBX 16.4M
- HOTH 15.6M
- IPO Year
- SYBX N/A
- HOTH 2019
- Fundamental
- Price
- SYBX $1.71
- HOTH $1.75
- Analyst Decision
- SYBX
- HOTH Strong Buy
- Analyst Count
- SYBX 0
- HOTH 3
- Target Price
- SYBX N/A
- HOTH $4.00
- AVG Volume (30 Days)
- SYBX 21.1K
- HOTH 2.1M
- Earning Date
- SYBX 11-11-2025
- HOTH 11-11-2025
- Dividend Yield
- SYBX N/A
- HOTH N/A
- EPS Growth
- SYBX N/A
- HOTH N/A
- EPS
- SYBX N/A
- HOTH N/A
- Revenue
- SYBX N/A
- HOTH N/A
- Revenue This Year
- SYBX N/A
- HOTH N/A
- Revenue Next Year
- SYBX N/A
- HOTH N/A
- P/E Ratio
- SYBX N/A
- HOTH N/A
- Revenue Growth
- SYBX N/A
- HOTH N/A
- 52 Week Low
- SYBX $0.90
- HOTH $0.65
- 52 Week High
- SYBX $1.96
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- SYBX 69.98
- HOTH 70.75
- Support Level
- SYBX $1.45
- HOTH $1.53
- Resistance Level
- SYBX $1.77
- HOTH $1.87
- Average True Range (ATR)
- SYBX 0.07
- HOTH 0.14
- MACD
- SYBX 0.03
- HOTH 0.05
- Stochastic Oscillator
- SYBX 83.33
- HOTH 80.15
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).